Disease |
Disease |
Method |
Sample |
Expression pattern |
Dysfunction type |
Description |
PMID |
Source |
Wilms' tumor |
N/A |
renal and haematopoietic cells |
down-regulated |
expression |
Both wt1-as and the novel awt1 transcript are imprinted in normal kidney with expression confined to the paternal allele. |
14681303 |
|
acute myeloid leukemia |
qPCR etc. |
bone marrow tissue |
differential expression |
epigenetics |
The incidence of WIT-1 methylation in primary refractory AML was significantly higher than that noted in chemosensitive AML. |
10340388 |
LncRNADisease Lnc2Cancer
|
acute myeloid leukemia |
qPCR etc. |
Bone marrow |
up-regulated |
Interaction |
In AML, there is often abnormal splicing of WT1-AS, which may play a role in the development of this malignancy. |
17940140 |
LncRNADisease Lnc2Cancer
|
Wilms' tumor |
qPCR etc. |
Bone marrow |
up-regulated |
Interaction |
WT1 is a gene that is mutated in Wilms' tumor (WT) and acute myeloid leukaemia (AML) and has an antisense transcript (WT1-AS), which was found to regulate WT1 protein levels. |
17940140 |
LncRNADisease Lnc2Cancer
|
gastric cancer |
qPCR etc. |
gastric cancer tissue, cell lines (SGC7901, BGC823, MKN45, MKN28, NCI-N87, AGS, HS-746T, GES-1) |
down-regulated |
expression |
We found that WT1-AS expression was significantly down-regulated in tumor tissues compared to matched adjacent non-tumor tissues. The WT1-AS expression level was also associated with tumor size and the clinicopathological stage. Cell proliferation, migration, and invasion were inhibited, and the proportion of G0/G1 cells increased when WT1-AS was ectopically-expressed in gastric cancer cells. Furthermore, ectopic expression of WT1-AS was demonstrated to inhibit tumor growth and metastasis in vivo. Finally, we found that WT1-AS overexpression could decrease ERK protein phosphorylation. |
26449525 |
Lnc2Cancer
|
Wilms' tumor |
qPCR, Southern blot, knockdown etc. |
Wilms' tumor tissue |
differential expression |
epigenetics |
A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesis. |
17210670 |
LncRNADisease Lnc2Cancer
|
hepatocelluar carcinoma |
qPCR, Western blot, Luciferase reporter assay etc. |
hepatocellular carcinoma tissue |
down-regulated |
interaction |
WT1-AS expression correlated negatively with WT1 expression in HCC tumor tissue. Kaplan-Meier curve analysis revealed that WT1-AS expression is a reliable indicator of HCC prognosis. The downregulation of WT1 expression by WT1-AS promoted cell apoptosis by suppressing the JAK/STAT3 signaling pathway. Bioinformatics analysis showed that WT1-AS downregulates WT1 by binding to the TATA region of the WT1 promotor. WT1-AS was also able to reverse WT1-mediated resistance to Dox based chemotherapy in HCC cells |
26462627 |
Lnc2Cancer
|
Wilms' tumor |
Southern blot analysis, RT-PCR |
kidney |
up-regulated |
epigenetics |
Wts display hypomethylation and biallelic expression of wt1-as. |
10811108 |
|
|